



# Notice of annual general meeting and explanatory memorandum

**3D Medical Limited**

ACN 007 817 192

---

**Date:** Thursday, 12 November 2015

**Time:** 11.00 am (Melbourne time)

**Venue:** RSM Bird Cameron Partners,  
Level 21, 55 Collins Street  
Melbourne, Victoria, 3000

---

# NOTICE OF 2015 ANNUAL GENERAL MEETING

NOTICE is given that the 2015 Annual General Meeting of 3D Medical Limited ACN 007 817 192 will be held at RSM Bird Cameron Partners, Level 21, 55 Collins Street, Melbourne, Victoria, 3000 on Thursday, 12 November 2015 at 11.00 am (Melbourne time).

## BUSINESS OF THE MEETING

Shareholders are invited to consider the following items of business at the Annual General Meeting:

### 1. Financial and related reports

Financial and related reports	
Description	To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 30 June 2015.

### 2. Adoption of Remuneration Report (Non-binding resolution)

Resolution 1	Adoption of Remuneration Report (Non-binding resolution)
Description	Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the 2015 Annual Report and is available from the Company's website ( <a href="http://www.3dmedical.com.au">www.3dmedical.com.au</a> ). In accordance with section 250R of the Corporations Act, the vote on this resolution will be advisory only and will not bind the directors or the Company.
Resolution (Ordinary)	To consider and, if thought fit, pass the following resolution as an <b>ordinary resolution</b> :  <i><b>"THAT the Remuneration Report of the Company and its controlled entities for the year ended 30 June 2015 be adopted."</b></i>
Voting Exclusion	<p>The Company will disregard any votes cast on this resolution (in any capacity, whether as proxy or as shareholders) by any of the following persons:</p> <ul style="list-style-type: none"><li>(a) Key Management Personnel; and</li><li>(b) Closely Related Parties of Key Management Personnel.</li></ul> <p>However, the Company need not disregard a vote if it is:</p> <ul style="list-style-type: none"><li>(c) cast by a person as a proxy appointed in accordance with the directions of the proxy form that specifies how the proxy is to vote on Resolution 1; and the vote is not cast on behalf of a person described in subparagraphs (a) and (b) above; or</li><li>(d) cast by the chair of the Meeting as proxy appointed in accordance with the directions of the proxy form for a person who is entitled to vote, and such appointment on the proxy form expressly authorises the chair to exercise the proxy even if the resolution is connected directly with the remuneration report; and the vote is not cast on behalf of a person described in subparagraphs (a) and (b) above.</li></ul>

### 3. Re-election of Directors

Resolution 2	Re-election of Mr Stephen Hewitt-Dutton as Director
Description	Mr Stephen Hewitt-Dutton retires as a Director in accordance with rule 20.2 of the Constitution, and being eligible, offers himself for re-election under rule 20.3 of the Constitution.
Resolution (Ordinary)	To consider and, if thought fit, pass the following resolution as an <b>ordinary resolution</b> :  <i>"THAT Mr Stephen Hewitt-Dutton, having retired from his office as a Director in accordance with rule 20.2 of the Constitution and, being eligible under rule 20.3 of the Constitution, having offered himself for re-election, be re-elected as a Director of the Company."</i>

Resolution 3	Re-election of Dr Nigel Finch as Director
Description	Dr Nigel Finch, who was appointed by the Directors to the Board on 7 May 2015, retires as a Director in accordance with rule 19.4 of the Constitution and ASX Listing Rule 14.4, and being eligible, offers himself for re-election under rule 19.4 of the Constitution.
Resolution (Ordinary)	To consider and, if thought fit, pass the following resolution as an <b>ordinary resolution</b> :  <i>"THAT Dr Nigel Finch, having been appointed as a Director on 7 May 2015, retires as a Director of the Company in accordance with rule 19.4 of the Constitution and ASX Listing Rule 14.4, and being eligible, having offered himself for re-election, be re-elected as a Director of the Company."</i>

### 4. Ratification of Issue of Shares

Resolution 4	Ratification of Issue of Shares
Description	The Company seeks shareholder ratification pursuant to ASX Listing Rule 7.4 for an issue of shares made by the Company on 25 June 2015. The shares were issued to Katia Pty Ltd in lieu of fees for consultancy services provided by Katia Pty Ltd to the Company.
Resolution (Ordinary)	To consider and, if thought fit, pass the following resolution as an <b>ordinary resolution</b> :  <i>"THAT for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 2,845,224 fully paid ordinary shares in the Company at a deemed issue price of \$0.009 per share to Katia Pty Ltd on the terms and conditions set out in the Explanatory Memorandum accompanying this Notice."</i>

<b>Voting Exclusion</b>	<p>The Company will disregard any votes cast on this resolution by any person who participated in the issue of the shares and any of their associates. However, the Company need not disregard a vote if it is cast by:</p> <ul style="list-style-type: none"> <li>(a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or;</li> <li>(b) the person chairing the Meeting as proxy for a person entitled to vote, in accordance with a direction on a proxy form to vote as the proxy decides.</li> </ul>
-------------------------	---

## 5. Ratification of Appointment of Auditor

<b>Resolution 5</b>	<b>Ratification of Appointment of Auditor</b>
<b>Description</b>	<p>The Company's previous auditor Bentleys Audit &amp; Corporate (WA) Pty Ltd resigned as auditor effective 30 April 2015 with the consent of ASIC. The Directors subsequently appointed RSM Bird Cameron Partners to act as auditors of the Company in accordance with section 327C(1) of the Corporations Act. Under section 327C(2) of the Corporations Act, RSM Bird Cameron Partners may hold office until the Annual General Meeting, at which point its office as auditor will need to be ratified by shareholders. The Company has received a notice of nomination, made pursuant to section 328B(1) of the Act, to appoint RSM Bird Cameron Partners as the Company's auditor at the 2015 Annual General Meeting, and accordingly proposes Resolution 5 to shareholders.</p>
<b>Resolution (Ordinary)</b>	<p>To consider and, if thought fit, pass the following resolution as an <b>ordinary resolution</b>:</p> <p><i><b>"THAT, for the purposes of section 327B(1)(b) of the Corporations Act and for all other purposes, RSM Bird Cameron Partners of Level 21, 55 Collins Street, Melbourne, Victoria 3000, having consented in writing to act as auditor of the Company, be appointed as auditor of the Company and its controlled entities."</b></i></p>

## 6. Approval of 10% Placement Capacity

<b>Resolution 6</b>	<b>Approval of 10% Placement Capacity</b>
<b>Description</b>	<p>3DM seeks approval of shareholders to be able to issue Equity Securities of up to an additional 10% of its issued capital by way of placements over a 12 month period, in addition to its ability to issue securities under Listing Rule 7.1.</p>
<b>Resolution (Special)</b>	<p>To consider and, if thought fit, pass the following resolution as a <b>special resolution</b>:</p> <p><i><b>"THAT for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to an additional 10% of its issued Equity Securities by way of placements over a 12 month period, on the terms and conditions set out in the Explanatory Memorandum accompanying this Notice."</b></i></p>

<b>Voting Exclusion</b>	<p>The Company will disregard any votes cast on this resolution by any person who may participate in the issue of Equity Securities under this resolution and a person who might obtain a benefit, except a benefit solely in the capacity of a holder of ordinary securities, if the resolution is passed and any associates of those persons.</p> <p>However, the Company need not disregard a vote if it is cast by:</p> <ul style="list-style-type: none"> <li>(a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or;</li> <li>(b) the person chairing the Meeting as proxy for a person entitled to vote, in accordance with a direction on a proxy form to vote as the proxy decides.</li> </ul>
-----------------------------	---

Dated 14 October 2015

**BY ORDER OF THE BOARD OF 3D MEDICAL LIMITED**



Alyn Tai  
**Company Secretary**

## QUESTIONS FROM SHAREHOLDERS

In order to provide an equal opportunity for all shareholders to ask questions of the Board, we ask you to submit in writing any questions to the Company or to the Company's auditor, RSM Bird Cameron, in relation to the conduct of the external audit for the year ended 30 June 2015, or the content of its audit report. Please send your questions via email to:

Ms Alyn Tai, Company Secretary, 3D Medical Limited  
alyn.tai@3dmedical.com.au

Written questions must be received by no later than **5.00pm (Melbourne time) on Friday, 6 November 2015**.

Your questions should relate to matters that are relevant to the business of the Annual General Meeting, as outlined in this Notice of Meeting and Explanatory Memorandum.

In accordance with the *Corporations Act 2001* (Cth) and the Company's policy, a reasonable opportunity will also be provided to shareholders attending the Annual General Meeting to ask questions about, or make comments upon, matters in relation to the Company including the Company's Remuneration Report for the year ended 30 June 2015.

During the course of the Annual General Meeting, the Chair will seek to address as many shareholder questions as reasonably practicable, and where appropriate, will give a representative of the auditor the opportunity to answer written questions addressed to it. However there may not be sufficient time to answer all questions at the Annual General Meeting. Please note that individual responses may not be sent to shareholders.

## VOTING INFORMATION

### Entitlement to vote at the Annual General Meeting

A determination has been made by the Board of the Company under regulation 7.11.37 of the *Corporations Regulations 2001* that the persons eligible to vote at the Annual General Meeting are those who are registered shareholders of the Company as at **7.00pm (Melbourne time) on Tuesday, 10 November 2015**, subject to any applicable voting exclusion.

### Voting by proxy

- (a) A shareholder entitled to attend and vote at the Annual General Meeting may appoint one proxy or, if the shareholder is entitled to cast 2 or more votes at the meeting, 2 proxies, to attend and vote instead of the shareholder.
- (b) Where 2 proxies are appointed to attend and vote at the meeting, each proxy may be appointed to represent a specified proportion or number of the shareholder's voting rights at the meeting.
- (c) A proxy need not be a shareholder of the Company.
- (d) A proxy may be an individual or a body corporate. If a body corporate is appointed, the proxy form must

indicate the full name of the body corporate and the full name or title of the individual representative of the body corporate for the meeting.

- (e) A proxy form accompanies this notice. If a shareholder wishes to appoint more than 1 proxy, they may make a copy of the proxy form attached to this notice. For the proxy form to be valid it must be received together with the power of attorney or other authority (if any) under which the form is signed, or a (notarially) certified copy of that power of authority **by 11.00am (Melbourne time) on Tuesday, 10 November 2015**:

- online: [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au) (select 'Voting' and follow the prompts to lodge your vote - see proxy form for further information)
- by post: 3D Medical Limited, c/- Link Market Services Limited, Locked Bag A14, Sydney South NSW 1235, Australia
- by hand: 1A Homebush Bay Drive, Rhodes NSW 2138 or Level 12, 680 George Street, Sydney NSW 2000 (Monday to Friday, 9.00am to 5.00pm)
- by facsimile: +61 2 9287 0309

### Proxy voting by the Chair

The *Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011* (Cth), imposes prohibitions on Key Management Personnel and their Closely Related Parties from voting their shares (or voting undirected proxies) on, amongst other things, remuneration matters.

However, the chair of a meeting may vote an undirected proxy (i.e. a proxy that does not specify how it is to be voted), provided the shareholder who has lodged the proxy has given an express voting direction to the chair to exercise the undirected proxy, even if the resolution is connected with the remuneration of a member of Key Management Personnel. If you complete a proxy form that authorises the Chair of the Meeting to vote on your behalf as proxy, and you do not mark any of the boxes so as to give him directions about how your vote should be cast, then you will be taken to have expressly authorised the Chair to exercise your proxy on Resolution 1. In accordance with this express authority provided by you, the Chairman will vote in favour of Resolution 1. If you wish to appoint the Chair of the Meeting as your proxy, and you wish to direct him how to vote, please tick the appropriate boxes on the form.

The Company's Chairman, Dr Nigel Finch, will chair the Meeting, and intends to vote all available undirected proxies in favour of each item of business.

If you appoint as your proxy any Director of the Company, except the Chairman, or any other Key Management Personnel or any of their Closely Related Parties and you do not direct your proxy how to vote on Resolution 1, he or she will not vote your proxy on that item of business.

# EXPLANATORY MEMORANDUM TO NOTICE OF 2015 ANNUAL GENERAL MEETING

## 1. Financial and related reports

Financial And Related Reports	
<b>Explanation</b>	<p>Section 317 of the Corporations Act requires the Company's financial report, directors' report and auditor's report for the financial year ended 30 June 2015 to be laid before the Company's 2015 Annual General Meeting. There is no requirement for a formal resolution on this item.</p> <p>The financial report contains the financial statements of the consolidated entity consisting of 3DM and its controlled entities.</p> <p>As permitted by the Corporations Act, a printed copy of the Company's 2015 Annual Report has been sent only to those shareholders who have elected to receive a printed copy. A copy of the 2015 Annual Report is available from the Company's website (<a href="http://www.3dmedical.com.au">www.3dmedical.com.au</a>).</p> <p>The Chair of the meeting will allow a reasonable opportunity at the meeting for shareholders to ask questions. Shareholders will also be given a reasonable opportunity at the meeting to ask the Company's auditor, RSM Bird Cameron, questions about its audit report, the conduct of its audit of the Company's financial report for the year ended 30 June 2015, the preparation and content of its audit report, the accounting policies adopted by the Company in its preparation of the financial statements and the independence of RSM Bird Cameron in relation to the conduct of the audit.</p>

## 2. Adoption of Remuneration Report (Non-binding resolution)

Resolution 1	Adoption of Remuneration Report (Non-binding resolution)
<b>Explanation</b>	<p>Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the Company's 2015 Annual Report and is available from the Company's website (<a href="http://www.3dmedical.com.au">www.3dmedical.com.au</a>).</p> <p>The Remuneration Report:</p> <ul style="list-style-type: none"> <li>describes the policies behind, and the structure of, the remuneration arrangements of the Company and the link between the remuneration of executives and the Company's performance;</li> <li>sets out the remuneration arrangements in place for each director and for certain members of the senior management team; and</li> <li>explains the differences between the basis for remunerating non-executive directors and senior executives, including the Chief Executive Officer.</li> </ul> <p>The vote on this item is advisory only and does not bind the Directors. However, the Board will take into account any discussion on this item and the outcome of the vote when considering the future remuneration policies and practices of the Company.</p>

<b>Voting Exclusion</b>	A voting exclusion statement applies to this resolution, as set out in the Notice.
<b>Board Recommendation</b>	The Directors unanimously recommend that shareholders vote in favour of adopting the Remuneration Report.
<b>Chair's available proxies</b>	The Chair of the Meeting intends to vote all available proxies in favour of this Resolution 1.

### 3. Re-election of Directors

<b>Resolution 2</b>	<b>Re-election of Mr Stephen Hewitt-Dutton as Director</b>
<b>Explanation</b>	<p>Rule 20.2 of the Constitution requires one third of the Directors (or if their number is not a multiple of three, the nearest whole number to one third), excluding the Managing Director if any, to retire at each Annual General Meeting of the Company. The Directors to retire under rule 20.2 are those who have held office as Director for the longest period of time since their last election to office. Rule 19.4 of the Constitution provides that any Director appointed to fill a casual vacancy or as an additional director must retire at the next Annual General Meeting but will not be counted towards the one third of Directors who must retire under rule 20.2.</p> <p>Mr Hewitt-Dutton is the only Director not subject to the requirement to retire under rule 19.4, and accordingly retires in accordance with rule 20.2. Being eligible under rule 20.3, Mr Hewitt-Dutton offers himself for re-election as Director.</p>
<b>About Mr Stephen Hewitt-Dutton</b>	<p>Mr Hewitt-Dutton was appointed to the Company's Board as an Independent Non-Executive Director on 6 October 2010.</p> <p>Mr Hewitt-Dutton has over 20 years of experience in corporate finance, accounting and company secretarial matters. He is an Associate Director of Trident Capital and holds a Bachelor of Business from Curtin University and is an affiliate of the Institute of Chartered Accountants.</p> <p>Mr Hewitt-Dutton has worked as a corporate finance executive for 10 years where he has assisted clients by providing equity market, IPO and M&amp;A advice and assistance. He has also held Financial Controller and Company Secretary positions for both public and private companies for in excess of 15 years.</p> <p>Mr Hewitt-Dutton is currently a director of Reclaim Industries Limited (ASX:RCM) and Flexiroam Limited (ASX:FRX).</p>
<b>Board Recommendation</b>	The Board, with Mr Hewitt-Dutton abstaining on making any recommendation, recommends that shareholders vote in favour of this Resolution 2.
<b>Chair's available proxies</b>	The Chair of the Meeting intends to vote all available proxies in favour of this Resolution 2.



<b>Resolution 3</b>	<b>Re-election of Dr Nigel Finch as Director</b>
<b>Explanation</b>	ASX Listing Rule 14.4 and rule 19.4 of the Company's Constitution require that the appointment of any Director who is appointed by the other Directors be ratified at the next Annual General Meeting following that Director's appointment. Dr Nigel Finch was appointed by the Board as a Director on 7 May 2015. Accordingly, Dr Finch retires as a Director and offers himself for re-election pursuant to ASX Listing Rule 14.4 and rule 19.4 of the Company's Constitution.
<b>About Dr Nigel Finch</b>	<p>Dr Finch was appointed to the Board as an Independent Non-Executive Director on 7 May 2015 and became the Company's Independent Non-Executive Chairman on 28 May 2015.</p> <p>Dr Finch is an experienced advisor and Non-Executive Director. He is currently the Principal of Saki Partners, an advisory firm that assists private and public sector clients with strategy, financial performance and corporate transactions. He has held director and senior management roles focused on strategy execution and managing financial performance in both early-stage and mature firms across a variety of industries and has significant experience in economic development and institution building throughout Asian markets. Previously, he was Associate Dean at the University of Sydney Business School. His successful academic career was preceded by a 20-year career as a financial controller, investment manager and company director.</p> <p>Dr Finch is currently a director of Skydive the Beach Group Limited (ASX:SKB) and was previously a director of KneoMedia Limited (ASX:KNM).</p>
<b>Board Recommendation</b>	The Board, with Dr Finch abstaining, recommends that shareholders vote in favour of Resolution 3.
<b>Chair's available proxies</b>	The Chair of the Meeting intends to vote all available proxies in favour of Resolution 3.

#### 4. Ratification of Issue of Shares

<b>Resolution 4</b>	<b>Ratification of Issue of Shares</b>
<b>Explanation</b>	The Company seeks shareholder ratification pursuant to ASX Listing Rule 7.4 for an issue of 2,845,224 fully paid ordinary shares on 25 June 2015. The shares were issued in lieu of fees for services provided by Katia Pty Ltd to 3DM.
<b>ASX Listing Rules</b>	<p>ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions under ASX Listing Rule 7.2, issue or agree to issue shares during any 12 month period in excess of 15% of the number of shares on issue at the commencement of that 12 month period without shareholder approval.</p> <p>ASX Listing Rule 7.4 sets out an exception to ASX Listing Rule 7.1, by permitting the ratification of previous issues of shares which were not made under a prescribed exception under ASX Listing Rule 7.2 or with shareholder approval, provided that such issues did not breach the 15% threshold set out by Listing Rule 7.1. If shareholders of a company approve the ratification of such previous issues of shares at a general meeting, those shares will be deemed to have been issued with shareholder approval for the purposes of ASX Listing Rule 7.1.</p>

<b>Reason for resolution</b>	<p>The effect of ratification in accordance with ASX Listing Rule 7.4 is the reinstatement of the Company's maximum capacity to issue further shares up to 15% of the issued capital of the Company, if required, in the next 12 months without requiring shareholder approval. The Directors believe that it is in the best interests of the Company that the Directors maintain their ability to issue up to 15% of the issued capital of the Company.</p> <p>The Directors consider it to be appropriate and prudent for approval to be sought at the Annual General Meeting, in respect of the relevant issue of shares made by the Company in the last twelve months. The Directors believe this approval will enhance the Company's flexibility to finance its operations through raising equity capital, should the Directors consider it to be in the best interests of the Company to do so.</p> <p>In particular, the Directors note that if this approval is not obtained at the Annual General Meeting, the Company may be required to incur additional costs and delay of convening an extraordinary general meeting of the Company if the Directors propose to issue securities which do not fall under an exception to the 15% rule in ASX Listing Rule 7.2.</p>
<b>Information required to be provided under the ASX Listing Rules</b>	<p>As stated above, the Company issued the shares in lieu of fees for services provided to the Company.</p> <p>In accordance with ASX Listing Rule 7.5, which contains requirements as to the contents of a notice sent to shareholders for the purposes of ASX Listing Rule 7.4, the following information is provided to shareholders:</p> <ul style="list-style-type: none"> <li>▪ <b>No. of shares issued</b> – 2,845,224</li> <li>▪ <b>Issue price per share</b> – Nil cash consideration; deemed issue price of \$0.009 per share</li> <li>▪ <b>Terms of shares</b> – Fully paid ordinary shares ranking pari-passu with other existing fully paid ordinary shares in the Company. The 2,845,224 shares are subject to voluntary escrow for one year from the date of issue, until 25 June 2016</li> <li>▪ <b>Recipient of issue</b> – Katia Pty Ltd, a consultant which provided services to the Company</li> <li>▪ <b>Use of funds raised</b> – No funds were raised from the issue of the shares. The shares were issued in lieu of fees for services provided to the Company.</li> </ul>
<b>Voting Exclusion</b>	A voting exclusion statement applies to this resolution, as set out in the Notice.
<b>Board Recommendation</b>	The Directors unanimously recommend that shareholders vote in favour of Resolution 4.
<b>Chairman's available proxies</b>	The Chairman of the Meeting intends to vote all available proxies in favour of this Resolution 4.

## 5. Ratification of Appointment of Auditor

Resolution 5	Ratification of Appointment of Auditor
<p><b>Background</b></p>	<p>Resolution 5 seeks shareholder ratification of the appointment of RSM Bird Carmon Partners (<b>RSM</b>) as auditor of the Company.</p> <p>The Company's auditor was previously Bentleys Audit &amp; Corporate (WA) Pty Ltd (<b>Bentleys</b>). Bentleys resigned as 3DM's auditor effective 30 April 2015 with ASIC's consent, which resulted in a casual vacancy arising in the office of 3DM's auditor.</p> <p>Section 327C of the Corporations Act provides that a public company may appoint an auditor to fill a casual vacancy, and the Company appointed RSM as its new auditor to fill this vacancy pursuant to section 327C(1) of the Corporations Act. Under sections 327C and 327B(1)(b) of the Corporations Act, an auditor appointed in this manner will hold office until the Company's next annual general meeting, where the appointment must be approved and confirmed by the Company's shareholders. Accordingly, the Company seeks this approval and confirmation from shareholders for RSM's appointment as auditor. RSM has provided to the Company written consent to act as auditor of the Company, in accordance with section 328A(1) of the Corporations Act.</p> <p>In accordance with section 328B(1) of the Corporations Act, which requires a member of the Company to nominate the auditor, Perco Group Pty Ltd (a shareholder of the Company) has nominated RSM as auditor by way of a notice to 3DM (<b>Notice of Nomination</b>) dated 7 October 2015. A copy of the Notice of Nomination has been provided to RSM, and is attached to this Notice of Meeting.</p> <p>Subject to the Company receiving shareholder approval at the Annual General Meeting, RSM's appointment as auditor of the Company will be formally confirmed and ratified.</p>
<p><b>Board Recommendation</b></p>	<p>The Directors unanimously recommend that shareholders vote in favour of Resolution 5.</p>
<p><b>Chairman's available proxies</b></p>	<p>The Chairman of the Meeting intends to vote all available proxies in favour of Resolution 5.</p>

## 6. Approval of 10% Placement Capacity

Resolution 6	Approval of 10% Placement Capacity
<p><b>General</b></p>	<p>Under Listing Rule 7.1, every listed entity has the ability to issue 15% of its issued capital without shareholder approval in a 12 month period. ASX Listing Rule 7.1A permits eligible small and mid-cap ASX-listed entities, subject to shareholder approval, to issue Equity Securities of up to an additional 10% of its issued capital by way of placements over a 12 month period, in addition to its ability to issue securities under Listing Rule 7.1 (<b>10% Placement Capacity</b>).</p> <p>The Company seeks shareholder approval under ASX Listing Rule 7.1A for the 10% Placement Capacity. The effect of this resolution will be to allow the Directors, subject to the conditions set out below, to issue Equity Securities under the 10% Placement Capacity without using the Company's 15% placement capacity under Listing Rule 7.1.</p> <p>Resolution 6 is a <b>special resolution</b>. Accordingly, at least 75% of votes cast by shareholders present and eligible to vote (in person or by proxy) at the meeting must be in favour of this resolution for it to be passed.</p>
<p><b>Eligibility</b></p>	<p>ASX-listed entities which have a market capitalisation of \$300 million or less, and which are not included in the S&amp;P/ASX 300 Index will be considered eligible to seek shareholder approval under Listing Rule 7.1A. As at the date of this Notice, the Company, which has a market capitalisation of less than \$300 million, is not included in the S&amp;P/ASX 300 Index. Accordingly, the Company is considered eligible to seek shareholder approval under Listing Rule 7.1A.</p>
<p><b>Formula</b></p>	<p>The exact number of additional Equity Securities that the Company may issue under the 10% Placement Capacity will be determined by a formula set out Listing Rule 7.1A.2 as follows:</p> $(A \times D) - E$ <p>Where:</p> <p><b>A</b> is the number of shares on issue 12 months before the date of issue or agreement:</p> <ul style="list-style-type: none"> <li>▪ plus the number of fully paid shares issued in the previous 12 months under an exception in ASX Listing Rule 7.2;</li> <li>▪ plus the number of partly paid shares that became fully paid in the previous 12 months (there are presently no partly paid shares on issue in the Company);</li> <li>▪ plus the number of shares issued in the previous 12 months with approval of shareholders under ASX Listing Rules 7.1 and 7.4. This does not include an issue of fully paid shares under the Company's 15% placement capacity without shareholder approval; and</li> <li>▪ less the number of shares cancelled in the previous 12 months.</li> </ul> <p><i>'A' has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity</i></p> <p><b>D</b> is 10%.</p> <p><b>E</b> is the number of Equity Securities issued or agreed to be issued under ASX Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that are not issued with the approval of shareholders under ASX Listing Rule 7.1 or 7.4.</p>

<b>Conditions of issue under the 10% Placement Capacity</b>	<p>There are a number of conditions applicable to the issue of Equity Securities under Listing Rule 7.1A, including a limitation on the discount to prevailing market price at which they may be issued, and additional disclosure requirements. A summary of these conditions are as follows:</p> <p>(a) Equity Securities issued under the 10% Placement Capacity can only be in a class of securities already quoted. At the date of this Notice, the Company only has one class of securities which are quoted, being ordinary shares.</p> <p>(b) The issue price of each Equity Security issued under the 10% Placement Capacity must be no less than 75% of the volume weighted average market price (<b>VWAP</b>) for Equity Securities in that class, calculated over the 15 trading days on which trades in that class were recorded immediately before either:</p> <ul style="list-style-type: none"> <li>i. the date on which the price at which the Equity Securities are to be issued is agreed; or</li> <li>ii. if the Equity Securities are not issued within 5 trading days of the date in paragraph (i), the date on which the securities are issued.</li> </ul>
<b>Period of validity of shareholder approval</b>	<p>In the event that the Company obtains shareholder approval of Resolution 6, such approval will cease to be valid upon the earlier of:</p> <p>(a) 12 months after the date of this Annual General Meeting, being 12 November 2016; or</p> <p>(b) if applicable, the date on which the Company's shareholders approve a change to the nature or scale of the Company's activities under Listing Rule 11.1.2, or the disposal of the Company's main undertaking under Listing Rule 11.2.</p> <p><b>(Placement Period)</b></p>
<b>INFORMATION TO BE PROVIDED TO SHAREHOLDERS UNDER ASX LISTING RULE 7.3A</b>	
<b>Minimum issue price</b>	<p>The issue price of each Equity Security issued under the 10% Placement Capacity must be no less than 75% of the VWAP for Equity Securities in that class, calculated over the 15 trading days on which trades in that class were recorded immediately before either:</p> <ul style="list-style-type: none"> <li>i. the date on which the price at which the Equity Securities are to be issued is agreed; or</li> <li>ii. if the Equity Securities are not issued within 5 trading days of the date in paragraph (i), the date on which the securities are issued.</li> </ul>
<b>Risk of dilution to shareholders</b>	<p>If Resolution 6 is approved by shareholders, any issue of Equity Securities under the 10% Placement Capacity may present a risk of economic and voting dilution of existing shareholders, including the risk that:</p> <ul style="list-style-type: none"> <li>▪ the market price of the Company's Equity Securities may be significantly lower on the relevant issue date than on the date of this Annual General Meeting; and</li> <li>▪ the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date.</li> </ul> <p>The table below shows the potential dilution of existing shareholders under various scenarios on the basis of:</p>

- an issue price of \$0.088 per share which was the closing price of the Company's shares on the ASX on 5 October 2015; and

the variable 'A' being calculated as the number of fully paid ordinary shares on issue on the date of this Notice, being 375,953,825. This assumes that all shares issued by the Company to date are ratified and approved by shareholders under Resolution 4.

The table also shows:

- two examples where variable 'A' has increased by 50% and 100%. The number of shares on issue in the Company may increase as a result of the issue of shares that do not require approval of shareholders (for example, pro-rata entitlement issues or scrip issues under takeover offers) or future placements of shares under Listing Rule 7.1 of up to 15% of issued capital that are approved at future general meetings of shareholders; and
- two examples of where the issue price of shares has decreased by 50% and increased by 100%.

VARIABLE 'A'		Dilution		
		50% decrease in issue price \$0.044	Issue price \$0.088	100% increase in issue price \$0.176
<b>Current Variable 'A'</b> 375,953,825 shares	<b>10% voting dilution</b>	37,595,383 shares	37,595,383 shares	37,595,383 shares
	<b>Funds raised</b>	\$1,654,196.83	\$3,308,393.66	\$6,616,787.32
<b>50% increase in current Variable 'A'</b> 563,930,738 shares	<b>10% voting dilution</b>	56,393,074 shares	56,393,074 shares	56,393,074 shares
	<b>Funds raised</b>	\$2,481,295.25	\$4,962,590.49	\$9,925,180.98
<b>100% increase in current Variable 'A'</b> 751,907,650 shares	<b>10% voting dilution</b>	75,190,765 shares	75,190,765 shares	75,190,765 shares
	<b>Funds raised</b>	\$3,308,393.66	\$6,616,787.32	\$13,233,574.64

The table has been prepared on the following assumptions:

- the Company issues the maximum number of shares available under the 10% Placement Capacity;
- no Options to acquire shares on issue in the Company are exercised;
- the 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue;
- the table does not show an example of dilution that may be caused to a particular shareholder as a result of placements under the 10% Placement Capacity based on that shareholder's holding at the date of the Annual General Meeting.
- the table shows only the effect of issues of Equity Securities under the 10% Placement Capacity in accordance with Listing Rule 7.1A and not under the 15% placement capacity under Listing Rule 7.1.

	<p>(f) the issue of Equity Securities under the 10% Placement Capacity consists only of shares.</p> <p>(g) the issue price is \$0.088, being the closing price of the Company's shares on the ASX on 5 October 2015.</p>
<b>Period of validity</b>	<p>The Company will only issue and allot the Equity Securities during the Placement Period. The approval under the Resolution 6 for the issue of the Equity Securities will cease to be valid in the event that shareholders approve a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking).</p>
<b>Reason for issue of shares under 10% Placement Capacity</b>	<p>The Company may seek to issue the Equity Securities for the following purposes:</p> <ul style="list-style-type: none"> <li>(a) non-cash consideration for the acquisition of the new assets, businesses or investments, in which event the Company will provide a valuation of the non-cash consideration as required by Listing Rule 7.1A.3; or</li> <li>(b) cash consideration, the proceeds of which will be applied to fund the Company's existing and future activities, appraisal of corporate opportunities, investment in new businesses (if any), the costs incurred in undertaking placement(s) of shares under Listing Rule 7.1.A and for general working capital.</li> </ul> <p>The Company will comply with the disclosure obligations under ASX Listing Rules 7.1A 4 and 3.10.5A upon issue of any Equity Securities.</p>
<b>Allocation policy</b>	<p>The Company may not issue any or all the Equity Securities for which approval is given and may issue the Equity Securities progressively as the Company places the Equity Securities with investors.</p> <p>The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Capacity. The identity of the allottees of Equity Securities will be determined on a case-by-case basis having regard to factors such as:</p> <ol style="list-style-type: none"> <li>1. fund raising options (and their viability) available to the Company at the relevant time;</li> <li>2. the effect of the issue of the Equity Securities on the control of the Company;</li> <li>3. the financial situation of the Company and the urgency of the requirement for funds; and</li> <li>4. advice from the Company's corporate, financial, legal and broking advisers.</li> </ol> <p>The allottees under the 10% Placement Capacity have not been determined as at the date of this Notice. It is intended that the allottees will be suitable professional and sophisticated investors, and other investors not requiring a disclosure document under section 708 of the Corporations Act, that are known to the Company and/or introduced by third parties.</p> <p>The allottees may include existing substantial shareholders and/or new shareholders, but the allottees will not be related parties of the Company.</p> <p>In the event that the shares under the 10% Placement Capacity are issued as consideration for the acquisition of businesses, assets or investments, it is likely that the allottees will be the vendors of such businesses, assets or investments.</p>

<b>Previous approval</b>	The Company has not previously sought or received approval under ASX Listing Rule 7.1A.
<b>Ranking of shares</b>	Any shares issued under the 10% Placement Capacity will rank equally with all other existing shares on issue in the Company.
<b>GENERAL INFORMATION</b>	
<b>Voting Exclusion</b>	A voting exclusion statement applies to this resolution, as set out in the Notice.
<b>Board Recommendation</b>	The Directors unanimously recommend that shareholders vote in favour of this resolution.
<b>Chairman's available proxies</b>	The Chairman of the Meeting intends to vote all available proxies in favour of this resolution.

## 7. Definitions

<b>3DM or Company</b>	3D Medical Limited ACN 007 817 192
<b>ASIC</b>	Australian Securities and Investments Commission.
<b>Constitution</b>	The Company's constitution
<b>Corporations Act</b>	<i>Corporations Act 2001</i> (Cth)
<b>Closely Related Party</b> (of a member of KMP of an entity)	Has the definition given to it by section 9 of the Corporations Act, and means: (a) a spouse or child of the member; or (b) a child of the member's spouse; or (c) a dependant of the member or of the member's spouse; or (d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealings with the entity; or (e) a company the member controls; or (f) a person prescribed by the regulations for the purposes of this definition (nothing at this stage).
<b>Director</b>	Means a director of the board of 3DM.
<b>Key Management Personnel or KMP</b>	Those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity.
<b>RSM</b>	Means RSM Bird Cameron Partners of Level 21, 55 Collins Street, Melbourne, Victoria 3000

**-ENDS-**



7 October 2015


Ms Alyn Tai  
Company Secretary  
3D Medical Limited  
Unit 4, 435 Williamstown Road  
Port Melbourne VIC 3207

**Notice of Nomination of RSM Bird Cameron Partners as Auditor of 3D Medical Limited**

Perco Group Pty Ltd (**Perco**), being a member of 3D Medical Limited ACN 007 817 192 (the **Company**), pursuant to section 328B(1) of the *Corporations Act 2001* (Cth), nominates RSM Bird Cameron Partners of Level 21, 55 Collins Street, Melbourne, Victoria 3000 as auditor of the Company at the next annual general meeting of the Company.

**SIGNED** for and on behalf of Perco Group Pty Ltd

Yours sincerely

A handwritten signature in black ink, appearing to read 'Frank Pertile', is written over a light blue rectangular background.

**Frank Pertile**  
Director of Perco Group Pty Ltd

## LODGE YOUR VOTE



### ONLINE

[www.linkmarketservices.com.au](http://www.linkmarketservices.com.au)



### BY MAIL

3D Medical Limited  
C/- Link Market Services Limited  
Locked Bag A14  
Sydney South NSW 1235 Australia



### BY FAX

+61 2 9287 0309



### BY HAND

Link Market Services Limited  
1A Homebush Bay Drive, Rhodes NSW 2138; or  
Level 12, 680 George Street, Sydney NSW 2000



### ALL ENQUIRIES TO

Telephone: +61 1300 554 474



X99999999999

## PROXY FORM

I/We being a member(s) of 3D Medical Limited and entitled to attend and vote hereby appoint:

### APPOINT A PROXY

☐ the Chairman of the Meeting (mark box)

OR if you are **NOT** appointing the Chairman of the Meeting as your proxy, please write the name of the person or body corporate you are appointing as your proxy

or failing the person or body corporate named, or if no person or body corporate is named, the Chairman of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the Annual General Meeting of the Company to be held at **11:00am (Melbourne time) on Thursday, 12 November 2015 at RSM Bird Cameron, Level 21, 55 Collins Street, Melbourne VIC 3000** (the **Meeting**) and at any postponement or adjournment of the Meeting.

**Important for Resolution 1:** If the Chairman of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chairman of the Meeting to exercise the proxy in respect of Resolution 1, even though the Resolution is connected directly or indirectly with the remuneration of a member of the Company's Key Management Personnel (**KMP**).

**The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business.**

### VOTING DIRECTIONS

Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting.

Please read the voting instructions overleaf before marking any boxes with an ☒

#### Resolutions

1 Adoption of Remuneration Report

For Against Abstain\*

☐ ☐ ☐

2 Re-Election of Mr Stephen Hewitt-Dutton as Director

☐ ☐ ☐

3 Re-Election of Dr Nigel Finch as Director

☐ ☐ ☐

4 Ratification of Issue of Shares

☐ ☐ ☐

5 Ratification of Appointment of Auditor

For Against Abstain\*

☐ ☐ ☐

6 Approval of 10% Placement Capacity

☐ ☐ ☐


\* If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

### SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED

Shareholder 1 (Individual)

Joint Shareholder 2 (Individual)

Joint Shareholder 3 (Individual)

Sole Director and Sole Company Secretary

Director/Company Secretary (Delete one)

Director

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the *Corporations Act 2001* (Cth).

## HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM

### YOUR NAME AND ADDRESS

This is your name and address as it appears on the Company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. **Please note: you cannot change ownership of your shares using this form.**

### APPOINTMENT OF PROXY

If you wish to appoint the Chairman of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chairman of the Meeting as your proxy, please write the name of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.

### DEFAULT TO CHAIRMAN OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chairman of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chairman of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Resolution is connected directly or indirectly with the remuneration of KMP.

### VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

### APPOINTMENT OF A SECOND PROXY

You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

- (a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and
- (b) return both forms together.

### SIGNING INSTRUCTIONS

You must sign this form as follows in the spaces provided:

**Individual:** where the holding is in one name, the holder must sign.

**Joint Holding:** where the holding is in more than one name, either shareholder may sign.

**Power of Attorney:** to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

**Companies:** where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the *Corporations Act 2001*) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

### CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate "Certificate of Appointment of Corporate Representative" should be produced prior to admission in accordance with the Notice of Meeting. A form of the certificate may be obtained from the Company's share registry or online at [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au).

### LODGEMENT OF A PROXY FORM

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below by **11:00am (Melbourne time) on Tuesday, 10 November 2015**, being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting.

Proxy Forms may be lodged using the reply paid envelope or:



#### ONLINE

[www.linkmarketservices.com.au](http://www.linkmarketservices.com.au)

Login to the Link website using the holding details as shown on the Proxy Form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" (Securityholder Reference Number (SRN) or Holder Identification Number (HIN) as shown on the front of the Proxy Form).



#### BY MAIL

3D Medical Limited  
C/- Link Market Services Limited  
Locked Bag A14  
Sydney South NSW 1235  
Australia



#### BY FAX

+61 2 9287 0309



#### BY HAND

delivering it to Link Market Services Limited\*  
1A Homebush Bay Drive  
Rhodes NSW 2138  
or  
Level 12  
680 George Street  
Sydney NSW 2000

\* During business hours (Monday to Friday, 9:00am–5:00pm)

**IF YOU WOULD LIKE TO ATTEND AND VOTE AT THE ANNUAL GENERAL MEETING, PLEASE BRING THIS FORM WITH YOU.  
THIS WILL ASSIST IN REGISTERING YOUR ATTENDANCE.**